RAPT Therapeutics says adding its CCR4 antagonist to Keytruda boosted response in PhII

RAPT Therapeutics is offering the first look at Phase II data suggesting that adding its small molecule CCR4 antagonist to Keytruda is leading to hoped-for responses — even in patients who otherwise wouldn’t be expected to respond. And it’s now looking for a partner to help take the program forward.

Click here to view original post